Peptide appearance Lyophilized form

Weight Loss

15 000+ verified orders

Tesamorelin

In stock

Tesamorelin is one of synthetically produced growth hormone releasing hormone (GHRH) analogues, which is utilized in the treatment of HIV-associated lipodystrophy, a condition characterized by abnormal fat distribution due to antiretroviral therapy in HIV-infected patients. By activating GHRH receptors in the pituitary gland, tesamorelin stimulates the release of growth hormone, subsequently promoting the synthesis of insulin-like growth factor-1 (IGF-1) in hepatocytes. This hormonal cascade mediates various effects, including growth, glucose uptake, and lipolysis. It has been researched also in cardiac diseases, peripheral nerve damage or even dementia.
Available strengths
92,90 €
Buy 2, get 1 free. €100 in paid peptide vials · water excluded
Bundle & save

Arrives 26 – 30 November to Europe

We accept Visa Mastercard Apple Pay (when supported) Google Pay (when supported) Klarna (where available) Shown at checkout

Tesamorelin

Price range: 92,90 € through 161,00 €

Trans-3-hexenoyl GHRH analogue for receptor and endocrine marker studies.

SKU: ADRIA-TESAMORELIN Categories: , ,

Compound information

Specifications

Molecular profile

Sequence
trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Molecular mass
5135.9 g/mol
CAS number
218949-48-5
Molecular formula
C221H366N72O67S

Material record

Physical appearance
White to off-white lyophilized powder
Solubility
Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
Product note
GHRH analogue research compound; supplied strictly for research use only.

Research overview

Tesamorelin

Description of Tesamorelin

Tesamorelin, a polypeptide consisting out of 44 amino acids of GHRH is specific for addition of trans-3-hexanoic acid to the peptide’s sequence, which makes the compound more stable in human plasma and also increases its half-life. Tesamorelin has been found effective in reducing visceral adiposity in patients with lipodystrophy, leading to its approval for clinical use in the United States in 2010. It was developed by Theratechnologies, Inc., and was not intended for weight loss or treatment of obesity but specifically targeted the reduction of excess abdominal fat associated with HIV medication-induced lipodystrophy. Its major effects are related to glucose and lipid metabolism, and it is being evaluated as a treatment of insulin resistance, nonalcoholic fatty liver, peripheral nerve regeneration or cardiovascular diseases. Lets have a look at several research results in the field of tesamorelin effects.

[1]

Research Confirmed Effects

Tesamorelin, a synthetic analog of growth hormone-releasing factor, addresses excess visceral adipose tissue (VAT) in patients with HIV-associated lipodystrophy, a condition characterized by body composition changes, including lipohypertrophy. Lipodystrophy adversely impacts patients' quality of life and is often linked to antiretroviral therapy (ART), particularly protease inhibitors. Tesamorelin's efficacy in reducing VAT has been demonstrated through randomized Phase 3 trials, showing significant reductions in VAT levels over six months of treatment. Notably, patient characteristics such as metabolic syndrome, elevated triglyceride levels, and white race are associated with a higher likelihood of VAT reduction with tesamorelin therapy.

Tesamorelin's approval in 2010 marked a significant advancement in the treatment of HIV-associated lipodystrophy, offering a targeted therapeutic approach to reduce excess adiposity in affected patients. Prior to its availability, treatment options for lipodystrophy were limited, often relying on lifestyle modifications and surgical interventions with varying degrees of success. Tesamorelin's effectiveness in reducing VAT by nearly 20% surpasses that of other available therapies, positioning it as a valuable intervention in managing lipodystrophy-related complications in HIV-infected patients. Thus, tesamorelin is 4 times more effective in reducing adipocity.

[2], [3]

HIV patients are also at increased risk of developing cardiovascular disease (CVD), mostly due to abnormal fat deposition, and also due to antiretroviral drugs. Tesamorelin demonstrates efficacy in reducing visceral adipose tissue (VAT) and improving metabolic parameters in HIV-infected patients with treatment-associated central fat accumulation. In a 26-week randomized trial involving 412 patients, daily subcutaneous injections of tesamorelin resulted in a significant reduction in VAT by 15.2% compared to a 5.0% increase in the placebo group. Moreover, tesamorelin treatment led to improvements in triglyceride levels, total cholesterol to HDL cholesterol ratio, and insulin-like growth factor I (IGF-I) levels. These metabolic benefits, including reduced VAT and improved lipid profiles, suggest a potential therapeutic role for tesamorelin in managing central fat accumulation in HIV-infected individuals.

Furthermore, responders to tesamorelin therapy, defined as those achieving ≥8% reduction in VAT, experienced greater reductions in triglyceride levels and improvements in glucose homeostasis compared to nonresponders over a 52-week treatment period. Notably, tesamorelin's effects on metabolic parameters are associated with the percentage change in VAT, indicating a direct correlation between VAT reduction and metabolic improvements. These findings underscore the potential of tesamorelin to not only reduce visceral adiposity but also mitigate cardiovascular risk factors in HIV-infected patients, offering a promising therapeutic strategy beyond conventional interventions like statins.

[4], [5]

Highly active antiretroviral therapy (HAART) is linked with various endocrine and metabolic complications, including altered pituitary growth hormone (GH) secretion in human immunodeficiency virus (HIV) infection, with about one-third of patients exhibiting biochemical GH deficiency (GHD). Patients with HIV often experience reduced spontaneous GH secretion and GH response to stimuli, particularly those with HIV-related lipodystrophy, potentially due to factors like fat accumulation. Although the exact mechanisms underlying GHD in HIV patients are complex and not fully understood, tesamorelin, as a GH releasing hormone analogue, shows promise in reducing visceral fat in HIV-infected individuals with lipodystrophy, offering a safer alternative to high-dose recombinant human growth hormone with fewer side effects.

[6]

Peripheral nerve injuries lead to motor and sensory deficits with limited therapeutic options available. Growth hormone (GH)-based therapies offer promise in accelerating axonal regeneration and limiting atrophy of denervated muscle and Schwann cells (SCs) before reinnervation, potentially improving outcomes post-surgery. GH-based treatments act on multiple tissues involved in nerve regeneration, offering multi-modal mechanisms and potential secondary benefits for bone, tendon, and wound healing. FDA-approved drugs augmenting the GH axis facilitate potential clinical translation for peripheral nerve injury treatment. Research suggests GH manipulation, like tesamorelin, may improve outcomes, offering potential FDA-approved interventions for this challenging condition.

[7]

The study conducted at the University of Washington School of Medicine involved thirty adults, including those with mild cognitive impairment (MCI), who self-administered daily subcutaneous injections of tesamorelin or placebo for 20 weeks. Brain magnetic resonance imaging and spectroscopy protocols, cognitive testing, and blood sampling were conducted at baseline and weeks 10 and 20, along with glucose tolerance tests before and after intervention. Results showed increased GABA levels in all brain regions, increased NAAG levels in the frontal cortex, and decreased MI levels in the posterior cingulate after 20 weeks of GHRH administration, suggesting a potential mechanism for the favorable effects on cognition observed in adults with MCI and older adults.

This evidence supports the effectiveness of GHRH analogues like tesamorelin in enhancing cognition in early stages of dementia, suggesting a potential avenue for treatment. The findings highlight the modulation of inhibitory neurotransmitter and brain metabolite levels as a mechanism underlying the cognitive benefits observed with GHRH administration. These results not only offer promise for the treatment of dementia but also suggest new directions for research in the quest for a cure or preventative measures against cognitive decline.

[8]

All presented information is based on scientific publications which can be found in

For laboratory purposes and personal observation only. Not for human consumption.

Laboratory care

Handling

Peptides in transport

Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.

Storage of lyophilized peptides

Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:

  • Room temperature (15–25 °C): Up to 3 months
  • Refrigerated (2–8 °C): Up to 6 months
  • Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)

Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.

Storage of reconstituted peptides

Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.

The following storage conditions are generally recommended:

  • Room temperature (15–25 °C): Avoid prolonged storage
  • Refrigerated (2–8 °C): Typically 4–8 weeks
  • Frozen (-20 °C or below): Up to 3–4 months

To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.

Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.

Analytical documentation

Tests

Latest published result

Liquilabs s.r.o.Signed Certificate of Analysis · 10mg

> 99.8%Purity by HPLC

Batch number
0012924
Tested
2026-06-22

Recorded QC panel

AssayPeptide screening
9.44 mg
PurityPeptide screening
> 99.8%
Identity (FTIR)FTIR spectrum
997
Identity (RT)Retention time
0.999
Bacterial EndotoxinUSP / Eur. Ph. 2.6.14
< 0.001 EU/mg

These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.

See all test results

Signed certificate

Source record

References

1.

„LiverTox: Clinical and Research Information on Drug-Induced Liver Injury“, 2018 [Internet].

2.

Clinical Review Report: Tesamorelin (Egrifta). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2016.

3.

A. Mangili, J. Falutz, J.-C. Mamputu, M. Stepanians, and B. Hayward, “Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat,” PloS One, vol. 10, no. 10, p. e0140358, 2015. [PubMed]

4.

J. Falutz et al., “Metabolic effects of a growth hormone-releasing factor in patients with HIV,” N. Engl. J. Med., vol. 357, no. 23, pp. 2359–2370, Dec. 2007. [NEJM]

5.

T. L. Stanley et al., “Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin,” Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., vol. 54, no. 11, pp. 1642–1651, Jun. 2012. [PubMed]

6.

V. Rochira and G. Guaraldi, “Growth hormone deficiency and human immunodeficiency virus,” Best Pract. Res. Clin. Endocrinol. Metab., vol. 31, no. 1, pp. 91–111, 2017. [PubMed]

7.

S. H. Tuffaha et al., “Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury,” Expert Opin. Ther. Targets, vol. 20, no. 10, pp. 1259–1265, Oct. 2016. [PubMed]

8.

S. D. Friedman et al., “Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging,” JAMA Neurol., vol. 70, no. 7, pp. 883–890, Jul. 2013. [PubMed]

9.

National Center for Biotechnology Information

PubChem Compound Summary: Tesamorelin

Authoritative identity record for the compound sold under the Tesa catalogue name.

PubChem View source ↗
10.

Chemical Abstracts Service

CAS Common Chemistry: 218949-48-5

Authoritative CAS Registry Number record for Tesamorelin.

CAS Common Chemistry View source ↗
11.

Russo SC, Ockene MW, Arpante AK, et al. · 2024

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors

Primary clinical research report for the compound described as Tesamorelin.

AIDS · 10.1097/qad.0000000000003965 View source ↗
12.

Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S · 2010

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data

The Journal of clinical endocrinology and metabolism View source ↗
13.

Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK · 2019

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

The lancet. HIV View source ↗
14.

Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV · 2012

Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial

Archives of neurology View source ↗
15.

Lauritzen L, Amundsen ID, Damsgaard CT, Lind MV, Schnurr TM, Hansen T, Michaelsen KF, Vogel U · 2019

FADS and PPARG2 Single Nucleotide Polymorphisms are Associated with Plasma Lipids in 9-Mo-Old Infants

The Journal of nutrition View source ↗
16.

Sharma G, Ojha R, Noguera-Ortega E, Rebecca VW, Attanasio J, Liu S, Piao S, Lee JJ, Nicastri MC, Harper SL, Ronghe A, Jain V, Winkler JD, Speicher DW, Mastio J, Gimotty PA, Xu X, Wherry EJ, Gabrilovich DI, Amaravadi RK · 2020

PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma

JCI insight View source ↗

Customer reviews

4.7/5185+ reviews
View on Trustpilot ↗Checked 17 Nov 2026

Quality products,fast shipping,great refferal plan,only downside is that products in 4 mounths since my first order got more and more expensive ,but overall verry good experience.

Read full review →

More than 2 weeks for package dispatch. They promised one free peptide next time. Sent me new tracking number but package still wasn't delivered to fedex. Last package (much much cheaper) was delivered in less than week. I will update if they will send my package. ok,package sent.

Read full review →

Extremely satisfied with the product quality and overall experience. The customer service is polite and quick. All recommendations!

Read full review →

Trustworthy site with a huge catalog of products. Been purchasing from them for some time now never got disappointed. I could only recommend them.

Read full review →

Everything ok. With little problem with package, but after contact with Customer Service everything went right. Good quality of products

Read full review →

Excellent. Buying peptides online can be nerve wracking! But Adria are very transparent about all the checks and certifications. My experience with them was excellent. Great products at good prices and efficient P&P

Read full review →